Biography
Dr Cucina is Vice President, Genetic and Genomic Services, and Chief Health Information Officer, for the UCSF Health system. Working with the Chief Genomics Officer, he is responsible for the strategy and operations of UCSF’s clinical genetic and genomics laboratories and services, and for the analytics, software, and information infrastructure to further the missions of UCSF Health. Dr. Cucina is board certified in Clinical Informatics and Internal Medicine, and practices in Hospital Medicine at UCSF’s Parnassus Campus.

Biography
Sharmila Majumdar, Ph.D., obtained her Ph.D. degree from Yale University in Engineering and Applied Sciences. After a short stay at Yale she joined UCSF as an Assistant Professor in 1989. Her research on machine and deep learning has a focus on imaging; prior work has focused on imaging technology development and translational, development of image processing, computer vision has been focused in the areas of osteoporosis, osteoarthritis, and lower back pain. She is the Executive and Scientific Director of the Center for Intelligent Imaging at UCSF. She was selected as a fellow of the American Institute of Medical and Biological Engineers in 2004, a fellow of the International Society of Magnetic Resonance in Medicine (ISMRM) in 2008, and awarded the ISMRM Gold medal in 2016. She is an active participant in the PMWC meetings. Her work over the last three decades has been extensively supported by the NIH and industry.

Biography
Charlotte Nelson received her PhD from the University of California, San Francisco in Biological and Medical Informatics under the mentorship of Dr. Sergio Baranzini and Dr. Atul Butte. Here she envisioned the use of SPOKE, a heterogeneous knowledge graph, not solely as a graph for users to go from one node to another, but as a stage for biomedical innovation. This vision saw her embed the data from millions of patients onto SPOKE. Her research has showcased multiple clinical and pharmaceutical applications of SPOKE enhanced with real world data. Additionally, in collaboration with NASA, she showed that SPOKE’s capabilities could be expanded to basic science (non-medical) research to gain multi-domain insights of input datasets. In 2021, Mate Bioservices was launched, in partnership with UCSF, to harness the power of SPOKE with platforms and services to advance academic, clinical, and pharmaceutical research.

Talk
Beyond Data: A Knowledge Platform for Biomedical Research
Today’s most pressing biomedical problems will only be solved through multidisciplinary exchanges of data and knowledge. Mate Bioservices’ human-centric platforms and services leverage our powerful knowledge graph to enable this interchange. Now academic, pharmaceutical, and clinical researchers can accelerate innovation by investigating their private data through a multidisciplinary and multi-omics lens.

Biography
John is a biotechnology Translational Science & Medicine consultant with a comprehensive and deep understanding of the development and application of pioneering molecular procedures to the translation of research-grade biomarker assays into clinical-grade clinically adopted diagnostic tests. John oversaw the translation of an early stage research Next Generation sequencing test to a US government reimbursed and now widely adopted Laboratory Developed CLIA-CAP test for transplanted kidney rejection. He advises commercial translation efforts at Stanford University (SPARK) and University of California in San Francisco (CATALYST).

Biography
Justin Bingham joined CENTOGENE in 2017 and leads the Company’s business development and commercialization activities across pharma and biotech. Justin is a seasoned business executive with a track record of executing high value and successful partnerships within the healthcare sector. He brings vast experience in the commercialization of cutting-edge technologies that utilize high powered genomic sequencing. Prior to his role at CENTOGENE, Justin led business development activities for Synthetic Genomics, Inc. (SGI) across several industries, including vaccines, pharma, and life sciences. Additionally, Justin has held research positions at the Genomics Institute of the Novartis Research Foundation (GNF) and the exploratory biology research group at Pfizer, Inc. Justin completed his undergraduate work in Molecular Biology at the University of California, Santa Cruz, and holds an MBA from the Rady School of Business at the University of California, San Diego.

Biography
Rob is the Co-Founder and Chief Business Development & Analytics Officer for Vidence. His responsibilities include identifying business opportunities to leverage a growing volume of deep longitudinal clinical-genomic data for use in multiple healthcare channels including biopharmaceutical, provider and payer markets

Talk
Using AI/ML to Identify Patients at Risk for Missing Therapy
We will discuss a project implemented during the COVID-19 pandemic using AI/ML to identify patients at risk for not returning for therapy. The process of communications with the clinical staff and the results of the program.

Biography
The focus of my work and research is conception, design, development of technology, platforms, infrastructure, and methods for collaborative clinical research and optimization of clinical research in disease-specific networks. We introduced such innovative concepts as NeuroBANK®, a patient-centric platform and accelerated research environment, utilized by hundreds of investigators at 80+ clinical sites in 14 countries; PRO-ACT™, a harmonized anonymized dataset from 23 ALS clinical trials utilized for future clinical trials’ design and AI and ML modeling; and The SigNET™ Platform for unique and secure patient identification across research continuum. All three platforms have won the Best Practice Award (2013-2015-2018-2020) from Bio-IT World Congress in Precision and Translational Medicine category, as “outstanding example of how technology innovations and strategic initiatives can be powerful forces for change in the life sciences.” Other research: technologies for secure collaboration, integration, harmonization, and sharing of clinical and research information by all clinical research enterprise participants.

Talk
Data FAIRness for Precision Research
Research data are invaluable resource of disease-specific knowledge. FAIRnization of data makes possible for academia, foundations, and industry to create pre-competitive resources for applying AI/ML modeling in identification of disease biomarkers, patient subpopulations, and creating disease progression and disease staging models, i.e., precision research and knowledge stratification.

Biography
Greg Storm, PhD is co-founder and COO of TripleBlind. Previously, Greg worked at EyeVerify/Zoloz as the Research Director where he focused on the intersection of data and data science/analytics oriented research. He worked closely with the data and product teams and was responsible for staying ahead of global customer demands. Upon EyeVerify’s acquisition he focused on completing research projects and developing processes to manage the merger of EyeVerify’s world-class biometric research organization into Ant Financial. Greg came to EyeVerify from a robust 21 year career at Accenture where he was a Partner for the Service Line Management division. For multiple years he was responsible for internal management of Accenture’s North American Utility Industry Finance and Performance Management practice, a $100m+ business, spanning typical ERP implementations to Activity Based Management implementations, to HR/Payroll systems. During his tenure at Accenture Greg worked alongside CEO’s and CFO’s to develop and implement new business functions from scratch.

Biography
Dr. Sevinsky has leveraged over two decades of experience in systems biology and taken aim at transforming public health and infectious disease surveillance through innovative implementation of NGS and bioinformatics technologies. During a three year tenure at the Colorado Department of Public Health and Environment, he led several initiatives to build NGS testing and bioinformatics capacity at the state, regional and national levels. In 2019 Dr. Sevinsky’s ambitions to impact public health exceeded his role as a government scientist, resulting in the formation of Theiagen Genomics. Dr. Sevinsky and his team now work with over four dozen public health laboratories nationally, and more than a dozen internationally in Africa and Asia. Prior to his time in public health, Dr. Sevinsky held several positions in non-profit and industry, working in applied technologies for diverse applications such as biomarker identification and biofuel/biochemical production.

Biography
Gundolf graduated from the Universities of Hamburg and Goettingen, Germany, in structural bioinformatics and machine learning. He continued theoretical and experimental methods development and data analyses for biomolecular research at the European Molecular Biology Laboratory and at Stanford University. At UCSF, he leads the technical integration and automatic detection of structure within various modalities of patient-centered data, including clinical notes and genomics.

Talk
UCSF InformationCommons: Multifactor Data Science to Adv. PM

Biography
Erick has been leading Medical Affairs at PathAI for the last two years.  One of his main focuses has been the market access and reimbursement strategy for novel and innovative diagnostics, where he works with internal teams on evidence generation requirements and external stakeholders on advancing coverage and reimbursement for AI-based diagnostics.  Prior to joining PathAI, Erick served as Medical Director and Head of Medical Affairs for the Blue Cross Blue Shield Associations (BCBSAs) health technology assessment group, Evidence Street, as well as the BCBSA medical policy team.  Since completing his pathology residence and molecular genetic pathology fellowship at UCLA, he has engaged with healthcare technology evaluators and payers to facilitate coverage and reimbursement for new healthcare technologies such as next-generation sequencing and novel diagnostics.

Biography
Dr. Nigam Shah is Professor of Medicine (Biomedical Informatics) at Stanford University, and serves as the Associate CIO for Data Science for Stanford Health Care. Dr. Shah's research focuses on bringing machine learning to clinical use safely, ethically and cost-effectively. Dr. Shah was elected into the American College of Medical Informatics (ACMI) in 2015 and was inducted into the American Society for Clinical Investigation (ASCI) in 2016. He holds an MBBS from Baroda Medical College, India, a PhD from Penn State University and completed postdoctoral training at Stanford University.

Biography
Dr. Kaplan’s research centers around developing data-driven methods for problems in several application areas. He currently leads efforts developing advanced machine learning (ML) methods for healthcare and precision medicine applications. The focus of this work is on probabilistic approaches for noisy, heterogeneous, and irregularly sampled data streams, which present difficulties for many existing ML methods. One area is in traumatic brain injury (TBI), which has a large and diverse outcome space, in addition to arbitrary missingness patterns in clinical data points. The developed probabilistic methods allow for the analysis of patient subgroups and likelihood estimation over a large number of outcomes. Research in imaging involves the development of representation learning methods for brain MRI using a novel artificial neural network architecture. This approach compresses volumetric images and partitions the brain into regions that correspond across subjects in a purely data-driven approach.

Talk
Unsupervised Learning Approaches Using Messy Data for Precision Medicine
Unsupervised probabilistic models can be used to capture the underlying structure of data despite messy characteristics such as missingness. We use the models for traumatic brain injury data which consist of detailed records of clinical, blood biomarker, imaging, and comprehensive multidimensional outcome data.

Biography
Dr. Peter Yu's expertise lies in the intersection of medical informatics, healthcare operations and public policy. While President of the American Society of Clinical Oncology, ASCO launched CancerLinq, which aggregates medical oncology data across U.S. academic and community practices, and 2 journals; JCO Global Oncology and JCO Cancer Clinical Informatics (Associate Editor). In his position as Clinical Member, Memorial Sloan Kettering Cancer Center he is on the leadership team for the strategic partnership between MSK and Hartford HealthCare whose mission is to accelerate the dissemination of knowledge from academic medical centers to community healthcare systems. Hartford HealthCare is a 7-hospital system caring for 1/3 of the Connecticut population. Dr. Yu serves on Hutchinson Institute for Cancer Outcomes Research (HICOR) Fred Hutchinson Cancer Research Center External Advisory Board, California Cancer Registry Advisory Committee, Epic Systems Adult Oncology Steering Board, and the American Joint Committee on Cancer (AJCC) Implementation Committee.

Talk
Improving Health and Economic Outcomes with AI
Structured data in the EHRs of 2806 patients who received a total of 17,513 chemotherapy treatments was aggregated and de-identified to develop a predictive algorithm for risk of chemotherapy induced febrile neutropenia. Linear, tree-based or ensemble methods were developed and a model to optimize clinical and financial outcomes using only 20 clinical features was identified.

Biography
Amanda has worked on the development of INHERET since its inception and oversees all aspects of the marketing, product development, and customer service teams. She guides the development of plans, messaging, and content that translates business goals into effective marketing strategies and drives market leadership.

Biography
Dr. Amir Bahmani is the Director of Stanford Deep Data Research Computing Center. He has been working on large-scale distributed and parallel computing applications since 2008. He is an active researcher in the VA Million Veteran Program (MVP), Human Tumor Atlas Network (HTAN), the Human BioMolecular Atlas Program (HuBMAP), Stanford Metabolic Health Center (MHC), Stanford Integrated Personal Omics Profiling (iPOP) and Stanford Healthcare Innovation Lab. As a computer scientist, he is passionate about bridging the gap between computer scientists and biologists/physicians. He successfully launched Stanford University’s first Cloud Computing for Healthcare course, offered to students in Biology, Computer Science, Genetics, and Biomedical Data Science departments. His research draws on computationally intensive medical applications, cloud computing, data privacy in medical applications, database management systems, and pervasive and ubiquitous computing.

Talk
Deep Data in Precision Medicine
This talk provides a short set of examples for how to handle large-scale medical studies in a secure and scalable fashion. It assesses contemporary realities, identifies potentially promising research directions, and investigates the potential impact on the field of bioinformatics from a Computer Science perspective.

Biography
Michael is the CEO of EB Research Partnership, an innovative medical research organization dedicated to curing the life-threatening genetic skin disease Epidermolysis Bullosa (EB) and leading the way for rare diseases with a pioneering venture investing and technology business model. Michael previously served as the Director of Development for the Multiple Myeloma Research Foundation leading their successful $100 million Curing Cancer Now campaign. Previously, Michael spent over a decade in leadership at the actor and philanthropist Paul Newman’s Hole in the Wall Gang Fund, working on behalf of children and their families battling cancer and other life-threatening illness. Michael received his MBA from Yale University, CORe credential from Harvard Business School, and an undergraduate degree in Philosophy from the University of Kansas.

Biography
Calum MacRae is a physician and scientist who works on disease mechanisms, translational genomic medicine and digital innovation. He is the PI of the AHA/Verily/AstraZeneca/Quest Diagnostics funded One Brave Idea program and the Apple Heart & Movement Study, as well as an Associate Member of the Broad Institute of Harvard and MIT and a Principal Faculty Member in the Harvard Stem Cell Institute. He was previously Chief of Cardiovascular Medicine at Brigham and Women's Hospital.

Talk
Encoding disease biology to automate care delivery
Data ingestion in medicine is typically a series of incompletely linked episodes. Systematizing all care transactions at an individual patient level offers the potential to create the data streams necessary to optimize chronic disease management, stratify individual risk in novel ways and reimagine clinical workflows.

Biography
Rajan Wadhwa is a senior leader in the Enterprise Data & Analytics group in Anthem Digital. He is accountable for Analytics in the Cost of Care, Clinical, Whole Person Profile as well as Product space. He is also responsible for Clinical Rules Engine, an application that creates Clinical intelligence used in Care Management, Disease Management and Patient Safety applications across Anthem. Rajan brings a broad and deep experience in Data and Analytics with over 22 years of experience. In his previous roles, he led Data and Analytics for Sales and Marketing group in a Financial Services company, led large Data and Analytics technology implementation in High Tech, Automotive, Real Estate and Telecom industries.

Biography
Gilbert S. Omenn, MD, PhD, is Harold T. Shapiro Distinguished University Professor of Computational Medicine Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. He was a Howard Hughes Medical Institute Investigator, longtime NCI-funded PI, physician genetic counselor at the University of Washington and CEO of the University of Michigan Health System. His research focus is proteogenomics of cancers. He chaired the global Human Proteome Project. He was president of AAAS; chaired the Presidential/ Congressional Commission on Risk Assessment and Risk Management and the Institute of Medicine 2012 report on Evolution of Translational Omics, and served on the boards of Amgen, Rohm Haas, Galectin, and Oncopia. Currently he is on the boards of Hastings Center for Bioethics, Center for Public Integrity, and Weizmann Institute..He has participated in the Personalized Medicine World Conferences for more than a decade.

Talk
Data Sciences for Proteogenomics of Cancers
NCI CPTAC-led multi-omics analyses of the molecular features of cancers identify drivers of proliferation and metastasis, subtypes of cancers and intra-tumoral heterogeneity, and targets for precision chemotherapy and immunotherapy, illustrated with clear cell renal adenocarcinomas.

Biography
Bob joined Datavant 4 years ago and in typical startup fashion has had a variety of roles and responsibilities since joining, from marketing to sales to product. Today, he manages the Life Sciences, Ecosystem Public Sector business at Datavant. He is motivated to build the world-class connectivity company the healthcare industry desperately needs. Prior to Datavant, Bob had several different roles that ranged from managing operations at a biopharmaceutical company to working as a restructuring and finance attorney. Bob holds a JD / MBA from Yale Law School after completing his undergraduate degree in Symbolic Systems at Stanford University.

Biography
Dr. John D. Halamka, M.D., M.S., is an American business executive and physician. He is president of the Mayo Clinic Platform, a group of digital and long-distance health care initiatives. Trained in emergency medicine and medical informatics, Halamka has been developing and implementing health care information strategy and policy for more than 25 years. He specializes in artificial intelligence, the adoption of electronic health records and the secure sharing of healthcare data for care coordination, population health, and quality improvement. In 2020, Halamka was elected to the National Academy of Medicine (NAM). Prior to his appointment at Mayo Clinic, he was chief information officer at Beth Israel Deaconess Medical Center. He is a practicing emergency medicine physician. As the International Healthcare Innovation Professor at Harvard Medical School, Halamka helped the George W. Bush administration, the Obama administration and governments around the world plan their health care information strategies.

Talk
The Breadth and Depth of Trustless Data Sharing Technology
This session brings together two sides of the data sharing innovation landscape – technologists and traditional healthcare systems. The group will discuss the breadth and depth of the impact data sharing technologies will have for insurers, digital health companies, and traditional healthcare systems seeking to innovate and push precision medicine forward.

Biography
Shivang Doshi currently serves as the Vice President of Global Payor Relations and Reimbursement at Paige, where he is focused on clinical and economic evidence generation, payor engagement and implementing pathways to drive payor coverage and reimbursement for AI-based diagnostics. Shivang has over 10 years of experiences in the life sciences industry developing global commercialization and market access strategies for numerous diagnostic technologies, including NGS, liquid biopsy, gene expression profiling, companion diagnostics and digital pathology. Previously, Shivang served as the VP of Precision Medicine at Boston Healthcare Associates (now part of Veranex) and conducted drug discovery research at Novartis.